Helping Patients Find Onexton: A Provider's Practical Guide

You've prescribed Onexton because it's the right treatment for your patient's acne. Now the callback comes: "My pharmacy doesn't have it." This scenario has become increasingly common, and it puts both providers and patients in a difficult position.

This guide offers a practical, step-by-step approach to helping your patients locate Onexton and maintain their treatment plan — or pivot effectively when Onexton proves inaccessible.

Current Availability Landscape

Onexton (Clindamycin Phosphate 1.2% / Benzoyl Peroxide 3.75%) is manufactured by Bausch Health and remains in active production. It is not on the FDA drug shortage list. However, real-world availability at the pharmacy level is constrained by:

• No generic equivalent: The 1.2%/3.75% formulation has no AB-rated generic on the market
• High wholesale cost: Retail pricing of $400–$990 per 50g pump discourages pharmacy stocking
• Cold chain requirements: Must be stored at 36°F–46°F with a 10-week expiration post-dispensing
• Low prescription volume: Insurance barriers suppress demand, creating a negative feedback loop for stocking

For the full clinical and market analysis, see our companion briefing: Onexton Shortage: What Providers and Prescribers Need to Know.

Why Patients Can't Find Onexton

When patients report they can't find Onexton, the issue typically falls into one of these categories:

1. Pharmacy doesn't stock it — Most common. Many chains and independents don't carry Onexton due to cost and storage concerns
2. Insurance denial — PA required and not yet approved, or plan excludes Onexton
3. Cost shock — Patient sees the price at the counter and can't afford it
4. Pharmacy confusion — Staff may not realize they can order it or may incorrectly report it as "discontinued"

Understanding which barrier your patient is facing helps you provide targeted support.

What Providers Can Do: 5 Actionable Steps

Step 1: Direct Patients to Medfinder

Medfinder for Providers is a free tool that checks real-time pharmacy inventory. You or your staff can search for Onexton and identify pharmacies near your patient that currently have stock. This eliminates the time-consuming process of patients calling pharmacy after pharmacy.

Consider adding the Medfinder link to your after-visit summary or prescription handouts for patients prescribed brand-name medications.

Step 2: Send the Prescription to a Pharmacy With Stock

Once you've identified a pharmacy with Onexton available (via Medfinder or a phone call), e-prescribe directly to that location. This is more efficient than sending it to the patient's usual pharmacy and hoping for the best.

If your patient prefers their regular pharmacy, you can also call the pharmacy and request a special order. Most wholesalers can deliver within 1–3 business days.

Step 3: Pre-Authorize Proactively

If you know the patient's insurance requires prior authorization for Onexton, initiate the PA at the time of prescribing — not after the pharmacy denial. Document:

• Previous trials of generic clindamycin/benzoyl peroxide (specify products and duration)
• Reason for treatment failure (irritation, non-response, adherence issues)
• Clinical rationale for the 3.75% benzoyl peroxide formulation (skin sensitivity, dryness concerns)

Proactive PA submission can save 1–2 weeks of back-and-forth.

Step 4: Provide Savings Information

Even when Onexton is found in stock, the price can be a deal-breaker. Equip your patients with cost-reduction options:

• Bausch + Lomb Access Program: Copay as low as $25 for commercially insured patients — activate at bauschaccessprogram.com or call 1-877-494-4372
• Bausch Health Patient Assistance Program: Free medication for uninsured/underinsured patients who meet income criteria — apply at bauschhealthpap.com
• SingleCare: Coupon pricing around $93 at select pharmacies
• Prescription discount cards: GoodRx, RxSaver, WellRx may offer reduced pricing

For a patient-facing resource you can share, see: How to Save Money on Onexton

Step 5: Have a Backup Plan Ready

Before the patient leaves your office, discuss what happens if Onexton proves inaccessible. Having an agreed-upon backup avoids a second appointment and keeps treatment on track.

Recommended alternatives:

• Generic Clindamycin/Benzoyl Peroxide 1.2%/2.5% (Acanya generic) — Closest formulation, $30–$80
• Generic Clindamycin/Benzoyl Peroxide 1%/5% (BenzaClin generic) — Higher BP, $25–$70
• Generic Clindamycin/Benzoyl Peroxide 1.2%/5% (Duac generic) — Same clindamycin dose, higher BP, $30–$90
• Epiduo Forte (Adapalene 0.3%/Benzoyl Peroxide 2.5%) — Different mechanism, no antibiotic

Workflow Tips for Your Practice

Integrating these steps into your clinical workflow doesn't have to be burdensome. Here are some efficiency tips:

Create a "Brand-Name Acne" Template

Develop a handout or EHR smart phrase that includes:

• Link to Medfinder for Providers
• Bausch savings program contact information
• List of generic alternatives with dosing
• Instructions for the patient if the pharmacy doesn't have stock

Delegate Inventory Checks

Train front-desk or MA staff to run a quick Medfinder search while the patient is still in the office. This takes 30 seconds and can prevent the callback cycle entirely.

Use Conditional Prescriptions

When prescribing Onexton, consider adding a conditional order: "If Onexton unavailable, dispense generic Clindamycin/Benzoyl Peroxide 1.2%/2.5%." Check your state's regulations on therapeutic substitution to ensure this approach is compliant.

Track Trends

If you're consistently hearing that patients can't find Onexton, it may be time to adjust your default prescribing to a generic alternative and reserve Onexton for cases where the lower benzoyl peroxide concentration is clinically important.

Final Thoughts

The Onexton access challenge is a solvable problem — but it requires providers to be a step ahead. By leveraging tools like Medfinder, proactively managing prior authorizations, connecting patients with savings programs, and having backup plans ready, you can keep acne treatment on track even when the pharmacy landscape doesn't cooperate.

For the broader clinical and market context, see our provider briefing: Onexton Shortage: What Providers and Prescribers Need to Know in 2026.